Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director David A. Socks sold 44,876 shares of the firm’s stock in a transaction on Friday, February 19th. The stock was sold at an average price of $47.18, for a total transaction of $2,117,249.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ:PHAT traded down $0.86 during midday trading on Tuesday, reaching $44.89. The company’s stock had a trading volume of 141,661 shares, compared to its average volume of 105,593. The firm has a market capitalization of $1.30 billion, a PE ratio of -3.27 and a beta of 1.32. Phathom Pharmaceuticals, Inc. has a twelve month low of $22.06 and a twelve month high of $64.54. The stock has a fifty day moving average of $40.32 and a 200 day moving average of $39.24. The company has a quick ratio of 8.21, a current ratio of 8.21 and a debt-to-equity ratio of 0.26.

A number of research analysts have issued reports on the stock. Guggenheim assumed coverage on shares of Phathom Pharmaceuticals in a report on Tuesday, February 2nd. They issued a “buy” rating and a $60.00 price target for the company. Jonestrading started coverage on shares of Phathom Pharmaceuticals in a report on Thursday, January 28th. They issued a “buy” rating for the company. Zacks Investment Research upgraded shares of Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 5th. BMO Capital Markets started coverage on shares of Phathom Pharmaceuticals in a research note on Wednesday, February 17th. They issued an “outperform” rating and a $63.00 price objective on the stock. Finally, Needham & Company LLC increased their price objective on shares of Phathom Pharmaceuticals from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, December 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $50.20.

Hedge funds have recently added to or reduced their stakes in the stock. Citigroup Inc. grew its position in Phathom Pharmaceuticals by 194.6% during the fourth quarter. Citigroup Inc. now owns 3,294 shares of the company’s stock valued at $110,000 after buying an additional 2,176 shares during the period. Trexquant Investment LP acquired a new stake in Phathom Pharmaceuticals during the fourth quarter valued at $208,000. Virtus ETF Advisers LLC grew its position in Phathom Pharmaceuticals by 6.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 6,635 shares of the company’s stock valued at $220,000 after buying an additional 393 shares during the period. Credit Suisse AG acquired a new stake in Phathom Pharmaceuticals during the fourth quarter valued at $264,000. Finally, Wells Fargo & Company MN grew its position in Phathom Pharmaceuticals by 30.9% during the fourth quarter. Wells Fargo & Company MN now owns 11,289 shares of the company’s stock valued at $375,000 after buying an additional 2,662 shares during the period. Institutional investors own 73.80% of the company’s stock.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

See Also: Price-Sales Ratio

Insider Buying and Selling by Quarter for Phathom Pharmaceuticals (NASDAQ:PHAT)

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.